Free Trial

Precision BioSciences (DTIL) Competitors

Precision BioSciences logo
$4.51 +0.20 (+4.64%)
As of 02:05 PM Eastern

DTIL vs. EPRX, ENGN, TLSA, CTMX, OGI, GNFT, FDMT, IPHA, VTYX, and DERM

Should you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include Eupraxia Pharmaceuticals (EPRX), enGene (ENGN), Tiziana Life Sciences (TLSA), CytomX Therapeutics (CTMX), Organigram Global (OGI), GENFIT (GNFT), 4D Molecular Therapeutics (FDMT), Innate Pharma (IPHA), Ventyx Biosciences (VTYX), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry.

Precision BioSciences vs. Its Competitors

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Eupraxia Pharmaceuticals presently has a consensus target price of $11.00, suggesting a potential upside of 99.82%. Precision BioSciences has a consensus target price of $47.00, suggesting a potential upside of 949.11%. Given Precision BioSciences' higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Eupraxia Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eupraxia Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
Precision BioSciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Precision BioSciences has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eupraxia PharmaceuticalsN/AN/A-$25.50M-$0.76-7.24
Precision BioSciences$68.70M0.72$7.17M-$2.01-2.23

Eupraxia Pharmaceuticals has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.

38.0% of Precision BioSciences shares are held by institutional investors. 4.0% of Precision BioSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Eupraxia Pharmaceuticals had 2 more articles in the media than Precision BioSciences. MarketBeat recorded 3 mentions for Eupraxia Pharmaceuticals and 1 mentions for Precision BioSciences. Eupraxia Pharmaceuticals' average media sentiment score of 1.43 beat Precision BioSciences' score of 0.28 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eupraxia Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Precision BioSciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Precision BioSciences' net margin of -42.99%. Precision BioSciences' return on equity of -69.26% beat Eupraxia Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Eupraxia PharmaceuticalsN/A -367.73% -112.23%
Precision BioSciences -42.99%-69.26%-29.30%

Summary

Eupraxia Pharmaceuticals and Precision BioSciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Precision BioSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DTIL vs. The Competition

MetricPrecision BioSciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$49.68M$2.90B$5.49B$8.93B
Dividend YieldN/A2.44%5.24%4.04%
P/E Ratio-2.2320.9327.1520.17
Price / Sales0.72191.67380.3794.17
Price / CashN/A41.7026.2128.59
Price / Book0.657.487.995.60
Net Income$7.17M-$55.04M$3.17B$248.41M
7 Day Performance8.47%5.32%3.51%6.03%
1 Month Performance-18.40%2.44%2.80%7.70%
1 Year Performance-51.83%5.19%34.00%20.86%

Precision BioSciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DTIL
Precision BioSciences
4.4834 of 5 stars
$4.51
+4.6%
$47.00
+942.1%
-53.2%$50.02M$68.70M-2.24200
EPRX
Eupraxia Pharmaceuticals
2.5234 of 5 stars
$5.76
+8.7%
$11.00
+91.0%
+120.2%$190.57MN/A-7.5829Positive News
Gap Up
High Trading Volume
ENGN
enGene
2.8002 of 5 stars
$3.64
-0.5%
$23.29
+539.7%
-58.4%$187.04MN/A-2.2131
TLSA
Tiziana Life Sciences
0.6786 of 5 stars
$1.58
-1.3%
N/A+84.3%$186.96MN/A0.008Positive News
CTMX
CytomX Therapeutics
3.908 of 5 stars
$2.27
+0.9%
$5.33
+134.9%
+83.7%$181.40M$138.10M4.73170
OGI
Organigram Global
0.5328 of 5 stars
$1.35
flat
N/A-12.3%$180.82M$117.47M13.50860News Coverage
Gap Down
GNFT
GENFIT
1.9822 of 5 stars
$3.73
+3.2%
$13.00
+249.0%
-11.4%$180.49M$67.00M0.00120Positive News
FDMT
4D Molecular Therapeutics
2.2647 of 5 stars
$3.71
-3.4%
$29.56
+696.6%
-81.3%$177.89M$40K-1.17120
IPHA
Innate Pharma
2.5384 of 5 stars
$1.82
-1.9%
$11.00
+506.1%
-10.1%$170.53M$21.77M0.00220Positive News
Gap Down
VTYX
Ventyx Biosciences
2.383 of 5 stars
$2.14
-8.5%
$10.00
+367.3%
-6.4%$166.52MN/A-1.2230
DERM
Journey Medical
1.9078 of 5 stars
$7.18
+0.6%
$9.50
+32.3%
+36.5%$166.33M$56.13M-18.4190Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:DTIL) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners